Recent advances in molecular profiling of bone and soft tissue tumors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38231260.
- Also identified by DOI 10.1007/s00256-024-04584-9 and PMC identifier 11303483.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The molecular characterization of soft tissue and bone tumors is a rapidly evolving field that has changed the perspective of how these tumors are diagnosed today. Morphology and clinico-radiological context still represent the cornerstone of diagnostic considerations but are increasingly complemented by molecular data that aid in objectifying and confirming the classification. The spectrum of analyses comprises mutation or gene fusion specific immunohistochemical antibodies, fluorescence in situ hybridization, DNA and RNA sequencing as well as CpG methylation profiling. This article provides an overview of which tools are presently available to characterize bone and soft tissue neoplasms molecularly, what limitations should be considered, and what conclusions can be drawn from the individual findings.
Medical subject headings
- Humans
- Soft Tissue Neoplasms
- Soft Tissue Neoplasms/diagnostic imaging
- Soft Tissue Neoplasms/genetics
- Bone Neoplasms
- Bone Neoplasms/diagnostic imaging
- Bone Neoplasms/genetics
- Biomarkers, Tumor
- Biomarkers, Tumor/genetics
- Gene Expression Profiling
- Gene Expression Profiling/methods
- Immunohistochemistry
- DNA Methylation
- Mutation